Perrigo Company plc (NYSE:PRGO) Director Sells $244,444.20 in Stock

Perrigo Company plc (NYSE:PRGO) Director Katherine C. Doyle sold 8,954 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $27.30, for a total value of $244,444.20. Following the completion of the sale, the director now owns 6,009 shares of the company’s stock, valued at $164,045.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Perrigo Trading Up 2.2 %

NYSE PRGO opened at $27.75 on Monday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.24 and a current ratio of 1.99. Perrigo Company plc has a 52 week low of $24.82 and a 52 week high of $34.60. The stock has a market capitalization of $3.78 billion, a price-to-earnings ratio of -396.43 and a beta of 0.49. The stock’s 50 day moving average price is $27.83 and its two-hundred day moving average price is $28.77.

Perrigo (NYSE:PRGO) last announced its quarterly earnings data on Friday, August 2nd. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.07. The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Perrigo had a positive return on equity of 6.79% and a negative net margin of 2.81%. Perrigo’s revenue for the quarter was down 10.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.63 EPS. As a group, analysts anticipate that Perrigo Company plc will post 2.57 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 17th. Investors of record on Friday, August 30th will be paid a $0.276 dividend. The ex-dividend date of this dividend is Friday, August 30th. This represents a $1.10 annualized dividend and a yield of 3.98%. Perrigo’s dividend payout ratio (DPR) is currently -1,571.43%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PRGO. StockNews.com upgraded Perrigo from a “hold” rating to a “buy” rating in a research report on Monday, August 5th. Piper Sandler reduced their price objective on shares of Perrigo from $36.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th.

Institutional Trading of Perrigo

Hedge funds have recently made changes to their positions in the business. Central Pacific Bank Trust Division bought a new position in shares of Perrigo in the first quarter valued at about $48,000. Parallel Advisors LLC raised its holdings in Perrigo by 69.1% in the 4th quarter. Parallel Advisors LLC now owns 2,009 shares of the company’s stock valued at $65,000 after acquiring an additional 821 shares during the period. Eagle Bay Advisors LLC lifted its position in Perrigo by 48.6% during the fourth quarter. Eagle Bay Advisors LLC now owns 2,156 shares of the company’s stock worth $69,000 after acquiring an additional 705 shares during the last quarter. TFC Financial Management Inc. boosted its holdings in shares of Perrigo by 39.7% during the first quarter. TFC Financial Management Inc. now owns 2,462 shares of the company’s stock worth $79,000 after acquiring an additional 700 shares during the period. Finally, Beach Investment Counsel Inc. PA acquired a new position in shares of Perrigo in the second quarter valued at approximately $72,000. 95.91% of the stock is owned by institutional investors and hedge funds.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.